contributes to the higher catalytic efficiency per histidine
residue (kcat/kuncat)/NHis observed in the larger histidine
oligomers independent of the increased binding to substrate 1.
In summary, the experiments above represent to our
knowledge the first example of catalyst discovery by screening
a SPOT library on solid support. The library screening showed
that multivalency effects previously observed in peptide
dendrimers for the hydrolysis of pyrenesulfonate ester 1 also
occur in linear peptides. While histidine and its dipeptide
behave as small molecule catalysts, the histidine tripeptide
and longer oligomers show preequilibrium substrate binding
by electrostatic interactions, with catalytic proficiencies
102–103-fold higher than 4-methyl imidazole. Their catalytic
proficiency per histidine residue reaches a plateau at the
level of the heptamer His7, with values within one order of
magnitude of previously identified peptide dendrimers such as
A3B and A3C for the same reaction.
Fig. 3 Inhibition of His15 catalysis of ester 1 hydrolysis by citrate
buffer at pH 5.5. Main plot: Lineweave–Burk plots with increasing
citrate. Inset: Dickson replot of KM/kcat. The 8-fold increase in citrate
from 5 to 40 mM causes a 5-fold increase in KM, a 2-fold increase in
This work was supported financially by the University
of Berne, the Swiss National Science Foundation, and the
Marie-Curie Training Network IBAAC.
k
cat, and a 1.2-fold increase in kuncat. Assay conditions as in Table 1.
Notes and references
dendrimers such as A3B and A3C which also carry 15 histidines.9
Note that the activity per His residue in peptide dendrimer
A3B represents a remarkable multivalency effect which is not
outperformed by dendrimers with higher number of histidines
(Fig. 2).
1 M. D. Toscano, K. J. Woycechowsky and D. Hilvert, Angew.
Chem., Int. Ed., 2007, 46, 3212–3236.
2 (a) R. Breslow, Acc. Chem. Res., 1995, 28, 146–153; (b) A. J. Kirby,
F. Hollfelder, A. J. Kirby and F. Hollfelder, From Enzyme Models
to Model Enzymes, 2009; (c) L. Baltzer and J. Nilsson, Curr. Opin.
Biotechnol., 2001, 12, 355–360.
Part of the increase in catalytic proficiency in the histidine
linear peptides was caused by stronger binding of substrate 1,
which increased gradually by up to three-fold between the
smallest enzyme model His3 (KM = 280 mM) and the histidine
oligopeptides His7–His15 (KM E 100 mM) or the peptide
dendrimer P65 (KM = 120 mM). The even lower KM of the
polycationic peptide P25 (KM = 42 mM) suggested an electro-
static component in substrate binding, presumably a salt
bridge between cations on the catalyst and the sulfonate
groups of substrate 1, as previously described for multivalent
histidine peptide dendrimer such as A3C.9 Electrostatic
substrate–catalyst interactions were evidenced for His15 by
the observation of a 2-fold increase in KM and 2-fold decrease
in kcat upon addition of 0.5 M KCl to the reaction buffer
(Table S4, ESIz). In addition, catalysis by His15 was inhibited
by citrate (Ki = 13 mM, Fig. 3), and by the tetraanion
pyrene-1,3,6,8-tetrasulfonate (Ki = 280 mM, Fig. S2, ESIz).
Acid–base titration of His15 showed an apparent pKa of
B5.4, which implies that eight of the fifteen histidines are
protonated and available for electrostatic binding of the
pyrene trisulfonate substrate 1 at the reaction pH of 5.5, while
seven occur as free base to catalyse the ester cleavage reaction.
The gradual lowering of the histidine pKa upon histidine
oligomerization pKa(His1) E 6.4 > pKa(His2) E 6.1 >
pKa(His3) E 6.0 > pKa(His8) E 5.7 > pKa(His15) E 5.4
indicates that a larger fraction of the histidines are available
as free bases to catalyse the reaction as the number of
histidine residues increases. This effect explains the 3-fold
higher catalytic activity of His1 (pKa E 6.4) over 4-methyl
imidazole (pKa E 7.5) in the hydrolysis of 1 and probably
3 (a) E. A. Davie, S. M. Mennen, Y. Xu and S. J. Miller, Chem. Rev.,
2007, 107, 5759–5812; (b) J. D. Revell and H. Wennemers, Curr.
Opin. Chem. Biol., 2007, 11, 269–278.
4 (a) L. Vial and P. Dumy, J. Am. Chem. Soc., 2007, 129, 4884–4885;
(b) L. Vial and P. Dumy, ChemBioChem, 2008, 9, 2950–2953.
5 (a) L. Crespo, G. Sanclimens, M. Pons, E. Giralt, M. Royo and
F. Albericio, Chem. Rev., 2005, 105, 1663–1681; (b) P. Niederhafner,
J. Sebestik and J. Jezek, J. Pept. Sci., 2005, 11, 757–788; (c)
J. Kofoed and J. L. Reymond, Curr. Opin. Chem. Biol., 2005, 9,
656–664.
6 (a) A. Esposito, E. Delort, D. Lagnoux, F. Djojo and
J. L. Reymond, Angew. Chem., Int. Ed., 2003, 42, 1381–1383;
(b) D. Lagnoux, E. Delort, C. Douat-Casassus, A. Esposito and
J. L. Reymond, Chem.–Eur. J., 2004, 10, 1215–1226; (c) C.
Douat-Casassus, T. Darbre and J. L. Reymond, J. Am. Chem.
Soc., 2004, 126, 7817–7826; (d) T. Darbre and J. L. Reymond,
Acc. Chem. Res., 2006, 39, 925–934.
7 (a) A. Clouet, T. Darbre and J. L. Reymond, Angew. Chem., Int.
Ed., 2004, 43, 4612–4615; (b) A. Clouet, T. Darbre and
J. L. Reymond, Biopolymers, 2006, 84, 114–123; (c) J. Kofoed
and J. L. Reymond, J. Comb. Chem., 2007, 9, 1046–1052;
(d) N. Maillard, A. Clouet, T. Darbre and J. L. Reymond, Nat.
Protoc., 2009, 4, 132–142; (e) N. Maillard, T. Darbre and
J. L. Reymond, J. Comb. Chem., 2009, 11, 667–675.
8 E. Delort, T. Darbre and J. L. Reymond, J. Am. Chem. Soc., 2004,
126, 15642–15643.
9 E. Delort, N. Q. Nguyen-Trung, T. Darbre and J. L. Reymond,
J. Org. Chem., 2006, 71, 4468–4480.
10 (a) S. Javor, E. Delort, T. Darbre and J. L. Reymond, J. Am.
Chem. Soc., 2007, 129, 13238–13246; (b) S. Javor and
J. L. Reymond, J. Org. Chem., 2009, 74, 3665–3674; (c) S. Javor
and J. L. Reymond, Isr. J. Chem., 2009, 49, 129–136.
11 C. Schmuck, U. Michels and J. Dudaczek, Org. Biomol. Chem.,
2009, 7, 4362–4368.
12 (a) R. Frank, Tetrahedron, 1992, 48, 9217–9232; (b) R. Frank,
J. Immunol. Methods, 2002, 267, 13–26; (c) K. Hilpert,
D. F. Winkler and R. E. Hancock, Nat. Protoc., 2007, 2,
1333–1349.
c
8748 Chem. Commun., 2010, 46, 8746–8748
This journal is The Royal Society of Chemistry 2010